Efficacy, effectiveness and side effects of medications used to prevent fractures

Journal of Internal Medicine

Volumn 277, Issue 6, 2015, Pages 690-706

  Reid, I R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Bisphosphonate; Calcium; Denosumab; Osteoporosis; SERM; Strontium; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; VITAMIN D; ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCIUM DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; THIOPHENE DERIVATIVE; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVERSE DRUG REACTION; ARTICLE; ATRIAL FIBRILLATION; BLOATING; BONE DENSITY; BONE TURNOVER; CALCIUM BALANCE; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ESOPHAGUS CANCER; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; EYE INFLAMMATION; FEMUR SUBTROCHANTERIC FRACTURE; FEVER; FRACTURE; FRACTURE TREATMENT; FRAGILITY FRACTURE; GASTROINTESTINAL IRRITATION; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALAISE; META ANALYSIS (TOPIC); MUSCULOSKELETAL PAIN; NEPHROLITHIASIS; OSSIFICATION; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SKIN MANIFESTATION; SPINE FRACTURE; THERAPY EFFECT; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; HIP FRACTURES; OSTEOPOROTIC FRACTURES; SPINAL FRACTURES; TREATMENT OUTCOME;

ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; CALCIUM COMPOUNDS; DIPHOSPHONATES; ETIDRONIC ACID; EVIDENCE-BASED MEDICINE; HIP FRACTURES; HUMANS; IMIDAZOLES; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RALOXIFENE; RISK ASSESSMENT; SPINAL FRACTURES; TERIPARATIDE; THIOPHENES; TREATMENT OUTCOME; VITAMIN D;

EID: 84929649834     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12339     Document Type: Article

References (113)

1. Curtis JR, Delzell E, Chen L et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res 2011; 26: 683-8.
2. Kanis JA, Passmore R. Calcium SUPPLementation of the diet. 2. BMJ 1989; 298: 205-8.
3. Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978; 92: 953-63.
4. Hunt CD, Johnson LK. Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies. Am J Clin Nutr 2007; 86: 1054-63.
5. Reid IR, Mason B, Horne A et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006; 119: 777-85.
6. Prince RL, Devine A, Dhaliwal SS et al. Effects of calcium SUPPLementation on clinical fracture and bone structure - Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166: 869-75.
7. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D SUPPLementation and the risk of fractures. N Engl J Med 2006; 354: 669-83.
8. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8.
9. Porthouse J, Cockayne S, King C et al. Randomised controlled trial of SUPPLementation with calcium and cholecalciferol (vitamin D) for prevention of fractures in primary care. BMJ 2005; 330: 1003-6.
10. Salovaara K, Tuppurainen M, Karkkainen M et al. Effect of vitamin D-3 and calcium on fracture risk in 65-to 71-year-old women: a population-based 3-year randomized, controlled trial-the OSTPRE-FPS. J Bone Miner Res 2010; 25: 1487-95.
11. Reid IR, Ames R, Mason B et al. Randomized controlled trial of calcium SUPPLementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008; 168: 2276-82.
12. Murad MH, Drake MT, Mullan RJ et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012; 97: 1871-80.
13. Reid IR, Bolland MJ. Calcium risk-benefit updated-New WHI analyses. Maturitas 2014; 77: 1-3.
14. Robbins JA, Aragaki A, Crandall CJ et al. Women's health initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause 2014; 21: 116-23.
15. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin-D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
16. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D-3 SUPPLementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13: 257-64.
17. Lips P, Chapuy MC, Dawson-Hughes B et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9: 394-7.
18. Thacher TD, Fischer PR, Pettifor JM et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341: 563-8.
19. Anderson JJB, Roggenkamp KJ, Suchindran CM. calcium intakes and femoral and lumbar bone density of elderly U.S. men and women: national health and nutrition examination survey 2005-2006 analysis. J Clin Endocrinol Metab 2012; 97: 4531-9.
20. Aptel I, Cance-Rouzaud A, Grandjean H. Association between calcium ingested from drinking water and femoral bone density in elderly women: evidence from the EPIDOS cohort. J Bone Miner Res 1999; 14: 829-33.
21. Kroger H, Tuppurainen M, Honkanen R et al. Bone mineral density and risk factors for osteoporosis - A population-based study of 1600 perimenopausal women. Calcif Tissue Int 1994; 55: 1-7.
22. Reid IR, Ames R, Evans MC et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 1992; 75: 45-51.
23. Mavroeidi A, Stewart AD, Reid DM et al. Physical activity and dietary calcium interactions in bone mass in Scottish postmenopausal women. Osteoporos Int 2009; 20: 409-16.
24. Uusi-Rasi K, Sievanen H, Pasanen M et al. Influence of calcium intake and physical activity on proximal femur bone mass and structure among pre- and postmenopausal women. A 10-year prospective study. Calcif Tissue Int 2008; 82: 171-81.
25. van Beresteijn ECH, van't Hof MA, Schaafsma G et al. Habitual dietary calcium intake and cortical bone loss in perimenopausal women: a longitudinal study. Calcif Tissue Int 1990; 47: 338-44.
26. Hansen MA, Overgaard K, Riis BJ et al. Potential risk factors for development of postmenopausal osteoporosis-examined over a 12-year period. Osteoporos Int 1991; 1: 95-102.
27. Burger H, Delaet CEDH, Vandaele PLA et al. Risk factors for increased bone loss in an elderly population - the Rotterdam study. Am J Epidemiol 1998; 147: 871-9.
28. Hosking DJ, Ross PD, Thompson DE et al. Evidence that increased calcium intake does not prevent early postmenopausal bone loss. Clin Therapeut 1998; 20: 933-44.
29. Dennison E, Eastell R, Fall CHD et al. Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 1999; 10: 384-91.
30. Hannan MT, Felson DT, Dawson-Hughes B et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 710-20.
31. Sirola J, Kroger H, Honkanen R et al. Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas 2003; 45: 159-67.
32. Reid IR, Ames RW, Evans MC et al. Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 1994; 79: 950-4.
33. Lewis JR, Zhu K, Prince RL. Adverse events from calcium SUPPLementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium SUPPLementation. J Bone Miner Res 2012; 27: 719-22.
34. Bolland MJ, Barber PA, Doughty RN et al. Vascular events in healthy older women receiving calcium SUPPLementation: randomised controlled trial. BMJ 2008; 336: 262-6.
35. Bolland MJ, Avenell A, Baron JA et al. Effect of calcium SUPPLements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: C3691.
36. Bolland MJ, Grey A, Gamble GD et al. Calcium and vitamin D SUPPLements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr 2011; 94: 1144-9.
37. Hsia J, Heiss G, Ren H et al. Calcium/vitamin D SUPPLementation and cardiovascular events. Circulation 2007; 115: 846-54.
38. McCloskey EV, Beneton M, Charlesworth D et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007; 22: 135-41.
39. Grey A, Bolland MJ, Wattie D et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94: 538-44.
40. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
41. Bonnick S, Broy S, Kaiser F et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007; 23: 1341-9.
42. Xue Y, Fleet JC. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology 2009; 136: 1317-27.
43. Lieben L, Masuyama R, Torrekens S et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest 2012; 122: 1803-15.
44. Yamamoto Y, Yoshizawa T, Fukuda T et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 2013; 154: 1008-20.
45. Reid IR, Bolland MJ, Grey A. Effects of vitamin D SUPPLements on bone mineral density: a systematic review and meta-analysis. Lancet 2014; 383: 146-55.
46. Abrahamsen B, Masud T, Avenell A et al. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010; 340: B5463.
47. Avenell A, Gillespie WJ, Gillespie LD et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. The Cochrane Database of Systematic Reviews 2005; Art.No.: CD000227.pub2.
48. Bischoff-Ferrari HA, Willett WC, Orav EJ et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40-9.
49. Sohl E, Heymans MW, De Jongh RT et al. Prediction of vitamin D deficiency by simple patient characteristics. Am J Clin Nutr 2014; 99: 1089-95.
50. Sanders KM, Stuart AL, Williamson EJ et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303: 1815-22.
51. Smith H, Anderson F, Raphael H et al. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women. A population-based, randomized, double-blind, placebo-controlled trial. Rheumatology 2007; 46: 1852-7.
52. Bischoff-Ferrari H, Dawson-Hughes B, Orav JE et al. Effects of 3 monthly vitamin D SUPPLementation strategies among fallers age 70 years and older: a double-blind randomized controlled trial. J Bone Miner Res 2012; 27(SUPPL. 1): S132.
53. Moyer VA, U. S. Preventive Services Task Force. Vitamin D and calcium SUPPLementation to prevent fractures in adults: US preventive services task force recommendation statement. Ann Intern Med 2013; 158: 691-6.
54. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2010 Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine, Washington DC.
55. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
56. Schwartz AV, Bauer DC, Cummings SR et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25: 976-82.
57. Black D, Reid I, Cauley J et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2013; 28(SUPPL. 1). http://www.asbmr.org/education/AbstractDetail?aid=683518f8-1743-494b-b218-24360a507d68.
58. Grey A, Bolland MJ, Horne A et al. Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial. Bone 2012; 50: 1389-93.
59. Black DM, Reid IR, Boonen S et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-54.
60. Cosman F, Cauley J, Eastell R et al. Who is at highest risk for new vertebral fractures after 3 years of annual zoledronic acid and who should remain on treatment? J Bone Miner Res 2011; 26(SUPPL. 1): S79.
61. Reid IR, Black DM, Eastell R et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J Clin Endocrinol Metab 2013; 98: 557-63.
62. Watts NB, Chines A, Olszynski WP et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19: 365-72.
63. Reid IR, Gamble GD, Mesenbrink P et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010; 95: 4380-7.
64. Wark JD, Bensen W, Recknor C et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 2012; 23: 503-12.
65. Patel DV, Horne A, House M et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 2013; 120: 773-6.
66. Grey A, Bolland M, Wong S et al. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97: 286-92.
67. Barrett-Connor E, Swern AS, Hustad CM et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012; 23: 233-45.
68. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007; 357: 712-3.
69. Lewiecki EM, Cooper C, Thompson E et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010; 64: 821-6.
70. Green J, Czanner G, Reeves G et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
71. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013; 346: f114.
72. Cardwell CR, Abnet CC, Cantwell MM et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-63.
73. Abrahamsen B, Pazianas M, Eiken P et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012; 27: 679-86.
74. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
75. Grbic JT, Landesberg R, Lin SQ et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32-40.
76. Grbic JT, Black DM, Lyles KW et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 2010; 141: 1365-70.
77. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes. J Am Dent Assoc 2008; 139: 23-30.
78. Pazianas M, Blumentals WA, Miller PD. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 2008; 19: 773-9.
79. Lin TC, Yang CY, Kao Yang YH et al. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int 2014; 25: 1503-11.
80. Lee SH, Chang SS, Lee M et al. Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2014; 25: 1131-9.
81. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 2009; 67: 35-43.
82. Manfredi M, Merigo E, Guidotti R et al. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg 2011; 40: 277-84.
83. Kwek EBK, Goh SK, Koh JSB et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39: 224-31.
84. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
85. Nieves JW, Bilezikian JP, Lane JM et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010; 21: 399-408.
86. Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-71.
87. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-37.
88. Schilcher J, Koeppen V, Aspenberg P et al. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014; 371: 974-6.
89. Dell RM, Adams AL, Greene DF et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27: 2544-50.
90. Meier RPH, Perneger TV, Stern R et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172: 930-6.
91. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
92. Papapoulos S, Jensen S, Wagman RB et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension. J Bone Miner Res 2013; 28(SUPPL. 1): S503.
93. Ferrari S, Wagman RB, Zapalowski C et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension. J Bone Miner Res 2013; 28(SUPPL. 1): S6.
94. Leder BZ, Tsai JN, Uihlein AV et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 2014; 99: 1694-700.
95. Cosman F, Eriksen EF, Recknor C et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26: 503-11.
96. Paparodis R, Buehring B, Pelley EM et al. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013; 19: E64-8.
97. ® post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Osteoporos Int 2014; 25(SUPPL. 2): 56-7.
98. Lindsay R, Hart DM, Forrest C et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; ii: 1151-3.
99. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
100. Grey AB, Stapleton JP, Evans MC et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636-41.
101. Reid IR, Eastell R, Fogelman I et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164: 871-9.
102. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -Results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45.
103. Sharifi M, Lewiecki EM. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol 2014; 7: 281-91.
104. Mirkin S, Ryan KA, Chandran AB et al. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas 2014; 77: 24-31.
105. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
106. Bang UC, Hyldstrup L, Jensen JEB. The impact of recombinant parathyroid hormone on malignancies and mortality: 7 Years of experience based on nationwide Danish registers. Osteoporos Int 2014; 25: 639-44.
107. Andrews EB, Gilsenan AW, Midkiff K et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012; 27: 2429-37.
108. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
109. Le Merlouette M, Adamski H, Dinulescu M et al. Strontium ranelate-induced DRESS syndrome. Ann Dermatol Venereol 2011; 138: 124-8.
110. Tan KW, Wang YS, Tay YK. Stevens-Johnson syndrome due to strontium ranelate. Ann Acad Med Singapore 2011; 40: 510-1.
111. Medicines and Healthcare Products Regulatory Agency (MHRA). Strontium ranelate (Protelos): risk of serious cardiac disorders-restricted indications, new contraindications, and warnings. Drug Saf Update 2013; 6: S1.
112. Dawson-Hughes B, Tosteson ANA, Melton LJ et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19: 449-58.
113. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33.